[34] Ulocuplumab is a fully humanized anti-CXCR4 monoclonal antibody, with half-life longer than the CXCR4 antagonist plerixafor, and that has been described as a pro-apoptotic agent in the context of both lymphoid and myeloid malignancies. The gene discussed is CXCR4; the disease is myeloid neoplasm.